In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Improved healthcare cost by reducing all unnecessary hospital admissions beyond 30-day readmissions: a new clinical model using interreality care for value-based paradigm

Session Digital health in clinical practice

Speaker Kareem Osman

Congress : ESC Congress 2018

  • Topic : e-cardiology / digital health, public health, health economics, research methodology
  • Sub-topic : Digital Health, Other
  • Session type : Rapid Fire Abstracts
  • FP Number : 1107

Authors : K Osman (Sunrise,US), I Dumitru (Hollywood,US), F Douglas (Sunrise,US), K Demuth (Sunrise,US), M Shen (Sunrise,US), R Perryman (Hollywood,US)

Authors:
K. Osman1 , I. Dumitru2 , F. Douglas1 , K. Demuth1 , M. Shen1 , R. Perryman2 , 1Duxlink Health - Sunrise - United States of America , 2Memorial Health Network - Hollywood - United States of America ,

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 225-226

Background: Reduction of 30-day hospital readmissions has been challenging to all hospitals in the paradigm shift from volume-based to value-based new healthcare in the US. It is even more difficult to reduce all unnecessary hospital admissions beyond readmissions due to intensive clinical care needs outside the hospital. Although telemedicine has been proposed as a new approach to reduce hospital readmissions, the current technology and clinical support are insufficient to provide care for high risk populations.

Methods: In addition to Conventional Care (CC: hospital/clinic), an Interreality Care (IRC) service was created for patients outside of the hospital with integration of: 1. CC; 2. On-Site Care using mid-level providers and testing (vitals, labs, imaging) at patients' residency; and 3. On-Line Care using 24/7 monitoring and specialty intervention (cardiology and pulmonology). A group of 112 Medicare patients with multiple hospitalizations enrolled in the service over 16 months. The duration of each hospitalization (General wards and ICU) and costs for the hospital stays for healthcare were compared between CC and IRC.

Results: The average number of hospitalizations per patient was 4.2 in CC and 0.8 in IRC. The average healthcare cost per patient was $59,980 for CC and $11,850 for IRC. The overall net cost savings between CC and IRC was $4.9M for healthcare.

Conclusion: To our knowledge, this is the first study to test the model of reduction of both unnecessary hospital admissions and readmissions using the integration of IRC. The preliminary results demonstrated that IRC with integrated Hospital, Clinic, On-Site, and On-Line care for patients at home can improve both quality and the cost of care, not only for 30-day readmissions, but for all healthcare admissions. Further study is warranted to examine implementation and scalability of the new model in a variety of healthcare settings, such as ACO, HMO and public health worldwide.

Table 1
Conventional CareInterreality Care
Admissions/Readmissions270/15137/38
Days of Hospital/ICU Stay2,283/194401/54
Total Cost for Healthcare$6,058,019$1,196,905
p<0.0001.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are